ClinicalTrials.gg
RecruitingNCT06716411CAREUpdated Apr 3, 2026

Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness

An interventional study of Acupuncture in Persian Gulf Syndrome, Gulf War Syndrome and Multiple Chronic Illnesses, sponsored by University of Utah. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by University of Utah · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This unblinded Phase II clinical trial will test the effects of individualized acupuncture treatments offered in extant acupuncture practices in the community; practitioners will have had at least 5 years of experience plus additional training provided by the study. Veterans with diagnosed symptoms of Gulf War Illness will be randomized to either six months of biweekly acupuncture treatments (group 1, n=100) or 2 months of waitlist followed by weekly acupuncture treatments (group 2, n=100). Measurements were taken at baseline, 2, 4 and 6 months. The primary outcome is the SF-36 physical component scale score (SF-36P).

Read the detailed description

Gulf War Illness (GWI), or chronic multisymptom illness (CMI), is a complex illness characterized by multiple symptoms, including fatigue, sleep and mood disturbances, cognitive dysfunction, and musculoskeletal pain, which are unexplained by physical and laboratory examinations. There is no standard of care treatment for this syndrome at this time. First defined by the Centers for Disease Control and Prevention (CDC) after the first Gulf War, it is commonly seen with a highly individualistic presentation, associated with clusters of symptoms and co-morbid medical diagnoses, including chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, arthralgia, digestive complaints, and mood-related psychiatric disorders, including depression, posttraumatic stress disorder (PTSD), and other anxiety disorders. It has been shown to be remarkably stable at 5- and 10- year follow-ups. Of the 700,000 service personnel deployed to the Persian Gulf, 100,000 veterans of the first Gulf War (Operation Desert Shield/Storm, years 1990-1991) have presented with medical complaints through clinical and registry programs. GWI is twice as prevalent in deployed veterans, and seen in 15% of non-deployed veterans.

CMI symptoms have been studied in cohorts of veterans in the United Kingdom, Canada, and Australia. The etiology of CMI is still unknown, and hypotheses involving exposures to vaccines, medications, pesticides, chemical munitions, and inhalation of depleted uranium dust and smoke from burning oil fields, have all been investigated inconclusively. Stress plays a likely role in the etiology of other multisymptom illnesses, such as irritable bowel syndrome (IBS), multiple chemical sensitivity and chronic headache. It is likely that veterans of the current war in Iraq and Afghanistan are exposed to similar deployment stressors and will benefit from an investigation of CMI and its treatment.

Acupuncture is an evidence-based, nonpharmacologic treatment commonly used for many symptoms affecting veterans and active military personnel, including pain. Acupuncture has shown efficacy for a variety of painful musculoskeletal disorders, as a treatment for both acute and chronic pain after amputation in military contexts, and in the treatment of related comorbidities such as fatigue, state, trait and situational anxiety, and depression. Acupuncture has shown effectiveness and is used in the Veterans Health Administration (VHA) and covered by Medicare for some conditions.

The L Conboy lab has completed multiple successful acupuncture trials in areas such as Irritable Bowel Syndrome, Carpel Tunnel Syndrome, and pelvic pain. Most recently the study team successfully completed a 3.5-year Congressionally Directed Medical Research Program (CDMRP) randomized controlled trial (RCT) "The Effectiveness of Acupuncture in the Treatment of Gulf War Illness". In that study, veterans chose a trained study acupuncturist in a location convenient to them. These community-based acupuncturists provided personalized acupuncture in a therapeutically informed dose. In the robust sample (n=104), investigators found a clinically and statistically significant improvement in pain after 2 months of treatment. After 6 months of treatment McGill Pain Scale values showed a 6-point improvement (p\<=0.001), and the physical component of the SF-36 (SF-36P) showed a 9-point improvement (p\<=0.003). Investigators also found statistically and clinically improvements in: the severity of veterans' self-reported main (p\<0.01) and secondary (p\<0.009) complaints as measured by the patient-centered Measure Your Medical Outcomes Profile (MYMOP) outcome measure, self-reported overall health from the SF-36P (p\<0.007), and fatigue (p\<0.05) based on the Multidimensional Assessment of Fatigue. Patient satisfaction with care and confidence in treatment was also very high (95% rated satisfied and confident). In addition, investigators found that the theoretically informed dose (2 sessions per week for 6 months) provided more relief for pain and poor function than did the comparison dose of one session per week, and that over 95% of symptom improvement for pain was maintained at 5-year follow up. Acupuncture at a sufficient dose is one of the only treatments found to be effective in improving pain and function in this hard-to-treat population while also addressing other symptoms in the patient's biopsychosocial presentation. Other high-quality science has shown that dosage is important for acupuncture treatment, and that treatment effects can persist long after acupuncture treatment has ended.

While this clinical data is very promising, equally important is furthering the understanding of the mechanisms of Gulf War Illness and successful treatments. Investigators conducted blood biomarker analyses using the collected blood samples from the parent trial, including collaborations with the Boston Biorepository, Recruitment and Integrative Network (BBRAIN) consortium at Boston University. Investigators found a number of interesting contrasts including significantly altered ether lipid metabolism in GWI, and that acyl-carnitine molecules are decreased in GWI, in agreement with previous reports. More recently, in collaboration with anti-aging researchers at Berkeley, investigators have found that acupuncture at the proper dose shifts the protein signature of GWI veteran to resemble a younger state (see below). In order to further elucidate the mechanisms underlying both GWI and successful treatments, the collection of blood biomarkers will be augmented by collection of physiological biomarkers potentially implicated in GWI symptoms.

Autonomic dysregulation has been demonstrated to be common among Veterans with GWI, according to both self-report and objective measures. The 31-item Composite Autonomic Symptom Score (COMPASS-31) scale assesses autonomic dysregulation. COMPASS-31 scores were positively associated with physical function in a GWI population, with gastrointestinal (GI) symptoms as the autonomic subscale most strongly correlated. A pilot study using heart rate variability (HRV) measurement reported parasympathetic activity (PNS) negatively associated with GWI symptoms, while sympathetic nervous system activity (SNS) was positively associated with symptoms. Further, some data suggest that treatment improvements in those with GWI are associated with improvements in autonomic regulation. For example, yoga and breathing techniques have demonstrated in multiple studies in veterans and non-veterans improvements in symptoms associated with GWI, including autonomic symptoms, chronic pain, and irritable bowel syndrome. Exploration of autonomic dysregulation in this study of acupuncture for GWI is thus proposed because acupuncture is associated with decreased autonomic symptoms. A recent meta-analysis concluded that real acupuncture has a superior effect over placebo acupuncture in increasing parasympathetic tone, though this has yet to be studied in GWI.

Gastrointestinal problems and fatigue are also highly prevalent among veterans with GWI. Autonomic dysregulation among veterans with GWI has been studied with respect to gastroparesis as demonstrated by a composite autonomic score of 3.7 in veterans with GI symptoms (vs 1.3 in controls) (p\<0.01). Previous work on GWI and HRV on the outcome of fatigue found a significant negative relationship between root mean square of successive differences of beat-to-beat intervals (RMSSD), a measure of PNS activity, and fatigue [r = -.0574]. This is consistent with literature indicating decreased parasympathetic activity to be a characteristic feature of both acute and daily levels of fatigue. Other work on acupuncture and HRV on the outcome of fatigue supports the investigation that acupuncture treatment is associated with decreased autonomic symptoms. Further a recent meta-analysis concluded that real acupuncture has a superior effect over placebo acupuncture in increasing parasympathetic tone, though this has yet to be studied in GWI. One study of acupuncture demonstrated decreased fatigue among patients with Chronic Fatigue Syndrome, and also reported instantaneous changes of HR after acupuncture therapy was administered.

If investigators confirm the previous clinical results, this data set will provide valuable documentation of the clinical, biological, and physiological changes that occur as veterans with GWI move to a healthier state. This will greatly improve current understanding of the Whole Health of GWI veterans, with applications to other clinical modalities and illnesses.

Subjects will be recruited via local advertisements and direct mailing to veterans on the Gulf War Registry, who live in one of the 6 areas identified by the team to have greater density of veterans diagnosed with Gulf War Illness. Through questionnaires, physician assessment, and medical histories, the investigators measured the severity of symptoms before beginning treatment, and after 2, 4 and 6 months of treatment. One group of patients received acupuncture evaluation and treatment twice per week for 6 months. A second group, for comparison purposes, will be monitored on a wait list for 2 months, and will then be offered weekly acupuncture for 4 months. The primary comparison is the difference at 6 months. Based on previous acupuncture research on fatigue, stress, and pain, including the parent study, the investigators expect this length of treatment will be enough for patients to receive significant benefit. The investigators also planed to collect samples of blood from the volunteers that will help identify possible disease mechanisms for the illness and track the effects of treatment.

02

Conditions studied

  • Persian Gulf Syndrome
  • Gulf War Syndrome
  • Multiple Chronic Illnesses
  • Occupational Diseases
  • War-Related Injuries
  • Wounds and Injuries

Keywords

  • Acupuncture
  • Gulf War Illness
  • Complex Medical Illness
  • Chronic Multisymptom Illness
  • Veteran
03

In context

Persian Gulf Syndrome

41 studies on the registry are indexed under Persian Gulf Syndrome; 10 are open to participants now.

This study's planned enrollment of 200 is above the median of 55 across 31 interventional studies indexed under Persian Gulf Syndrome.

Browse Persian Gulf Syndrome studies →

Lead sponsor

University of Utah is the lead sponsor of 994 studies on the registry; 175 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Deployed to the Gulf Theater of operations (as defined by 38 CFR 3.317, includes Iraq, Kuwait, Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the airspace above all of these locations) between August 1990 and the present date
  • Have at least 2 of the following symptoms from the 3 CDC clusters of symptom that have lasted for more than 6 months. Each symptom cluster must be characterized as mild-moderate or severe, with at least one symptom in each cluster required to be severe. The clusters are:

A. Fatigability: fatigue 24 hours or more after exertion B. Mood and Cognition: feeling depressed; feeling irritable; difficulty thinking or concentrating; feeling worried, tense, anxious; problems finding words; or problems getting to sleep C. Musculoskeletal: joint pain or muscle pain

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in another clinical trial
  • Have another disease that likely could account for the symptoms, as determined by our Medical Monitor
  • Severe psychiatric illness (in the last 2 years psychiatric hospitalization, suicidal attempt, alcohol or substance abuse, use of antipsychotic medication) as measured by the Primary Care Evaluation of Mental Disorder (Prime MD).
  • Unable to complete the protocol on based on the evaluation of the Medical Monitor.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Bi-weekly acupuncture treatment

    Bi-weekly acupuncture treatment

    Device: Acupuncture

  • Active comparator
    Wait list

    Wait list for 2 months followed by weekly acupuncture for 4 months

    Device: Acupuncture

Interventions

  • DeviceAcupuncture

    Sterile insertive needles are applied by licensed, experienced practitioners.

06

What researchers measure

Primary outcomes

  1. SF-36P

    Ten items addressing physical functioning which are part of a short-form health survey with 36 questions. Scores range between 0 and 100 with higher scores indicating better function.

    Time frame: 6 months

Other outcomes

  1. Blood Draw

    Blood draws will be used to examine levels of selected markers of inflammation, stress, and immune function. The units of measure would be relative to control, baseline or untreated. The following proteins will be evaluated: TRAIL-R1 (Tumor necrosis factor-Related Apoptosis-Inducing Ligand Recombinant protein 1); IL-16 (Interleukin 16) TIMP-1 (Tissue Inhibitor of MetalloProteinases-1); IL-15Ra (Interleukin 15 R alpha); CD27 (also known as Tumor necrosis factor receptor superfamily member 7 (TNFRSF7)); APJ (apelin receptor); SMAD5 (mothers against decapentaplegic homolog 5); uPAR (urokinase plasminogen activator surface receptor); FADD (Fas-associated death domain); MFGE8 (Milk fat globule epidermal growth factor 8); ICAM-1 (Intercellular adhesion molecule 1); TNFRSF27 (tumor necrosis factor receptor superfamily member 27); CCL25 (Chemokine ligand 25); TGFbR2 (transforming growth factor beta receptor 2); TLR4 (tool-like receptor 4)

    Time frame: 6 months

  2. McGill Pain Scale

    The McGill Pain scale is perhaps the most recognized and utilized pain measurement device across a range of ailments. This 15-item measure asks participants to describe the quality of their pain using various different descriptors (73). The McGill pain scale is 0-60 range, where the worse the pain the higher the number.

    Time frame: 6 months

  3. Heart rate variability (HRV)

    Signs and symptoms of autonomic dysfunction, including changes in heart rate variability (HRV), have been demonstrated among veterans diagnosed with GWI. Acupuncture has also demonstrated an impact the autonomic nervous system by effecting a shift away from sympathetic dominance and toward parasympathetic dominance. So, we propose to measure HRV parameters as a physiological biomarker of treatment effect. Specifically, the team will gather the following HRV data: heart rate (HR); respiratory rate (RR); standard deviation of normal-to-normal intervals (SDNN); root mean square of successive differences (RMSSD); pNN50 (percentage of consecutive normal sinus intervals that differ by more than 50 milliseconds); VLF (band of rhythms with periods between 25 and 300 s); LF (band of rhythms with periods between 7 and 25 s); any heart failure (HF); LF/HF (ration of low frequency to high frequency); and total power. HRV data will be extracted continuously from Fitbits worn by participants.

    Time frame: 6 months (starting two weeks before treatment starts until the end of treatment)

07

Study locations

3 of 10 sites recruiting
  • University of California, Berkeley
    Berkeley, California 94720, United States
    Not yet recruiting
    • Irina Conboy, PhD · Contact
  • Various
    Los Angeles, California 90015, United States
    Recruiting
    • CARE Study Research Team · Contactgwi@utah.edu · 801-646-8308
  • Various
    Colorado Springs, Colorado 80911, United States
    Not yet recruiting
    • CARE Study Research Team · Contactgwi@utah.edu · 801-646-8308
  • Various
    Denver, Colorado 80203, United States
    Not yet recruiting
    • CARE Study Research Team · ContactGWI@utah.edu · 801-646-8308
  • Various
    Tampa, Florida 33762, United States
    Recruiting
    • CARE Study Research Team · ContactGWI@utah.edu · 801-646-8308
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • Various
    Dallas, Texas 75231, United States
    Recruiting
    • CARE Study Research Team · ContactGWI@utah.edu · 801-646-8308
  • University of Utah
    Salt Lake City, Utah 84111, United States
    Not yet recruiting
  • Various
    Fairfax, Virginia 23235, United States
    Not yet recruiting
    • CARE Study Research Team · Contactgwi@utah.edu · 801-646-8308
  • Various
    Seattle, Washington 98116, United States
    Not yet recruiting
    • CARE Study Research Team · Contactgwi@utah.edu · 801-646-8308
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2024
First posted
Dec 4, 2024
StartActual
Feb 3, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2028
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06716411
Lead sponsor
University of Utah
Collaborators
United States Department of Defense, University of California, Berkeley, Beth Israel Deaconess Medical Center
Responsible party
Lisa J Taylor-Swanson (Principal Investigator, PhD, University of Utah) — Principal investigator
First posted
Dec 4, 2024
Start date
Feb 3, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Apr 3, 2026

Study contacts

Lisa Conboy
Contact
lisa_conboy@hms.harvard.edu
617-718-1917

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion